JPMorgan Adjusts Price Targets for Sainsbury and Emerson, Contrary to Recent Speculation
Key Takeaways JPMorgan (JPM) recently raised its price target for Emerson Electric (EMR) to $151 from $135, an increase of […]
Global Markets Rally on US Shutdown Progress, Consumer Wealth Hits Record, BOJ Navigates Trade Risks
Key Takeaways The U.S. Senate's advancement of funding legislation to end the government shutdown has ignited market optimism, propelling Nasdaq
Global Markets React as USTR Halts China Maritime Probe, US Air Travel Crisis Deepens, and SeaBank Pursues $150M Bond Issuance
Key Takeaways The U.S. Trade Representative (USTR) has announced a one-year suspension of actions in its Section 301 investigation into
Global Markets Eye China’s Trade Surges, Central Bank Moves, and India’s Upgraded Outlook
Key Takeaways Goldman Sachs has upgraded India equities to Overweight, projecting a Nifty target of 29,000 by end-2026, indicating a
Global Markets Rally on Shutdown Hopes, Gold Shines Amid Rate Cut Bets
Key Takeaways Global equity futures are advancing, with European and U.S. indices showing gains, driven by optimism surrounding a potential
Markets Rally on Shutdown Deal Hopes, Pfizer’s $10B Metsera Acquisition, While Economic Headwinds Persist
Key Takeaways A deal to end the U.S. federal government shutdown has been reached in the Senate, proposing to fund
Global Markets React to Japan’s Fiscal Shift, Surging Bond Yields, and European Gains
Key Takeaways Japan's Prime Minister Sanae Takaichi is poised to reassess the nation's fiscal balance surplus target, indicating a strategic
Global Markets Eye US Shutdown Resolution and Japan’s Fiscal Path
Key Takeaways The record-breaking US government shutdown appears to be nearing an end as a group of moderate Senate Democrats
RBA Signals Restrictive Policy and Late 2025 Rate Cuts Amidst US Government Funding Stalemate
Key Takeaways Reserve Bank of Australia (RBA) Deputy Governor Andrew Hauser emphasized that a key priority for Australia's economy is
AstraZeneca and Merck Announce Positive Phase 3 Trial Results for Baxdrostat and Enlicitide Decanoate
Key Takeaways AstraZeneca (AZN) announced that its investigational aldosterone synthase inhibitor, Baxdrostat, successfully met its primary endpoint in a Phase